Browse Antiretroviral agents topic

Research subtopic

Articles 1-24 out of 24 article(s) Title Author Type Date Words AIDS Patients with Serious Complications Benefit from Early Retroviral Use, Stanford Study Shows. Clinical report May 16, 2009 1202 Phase III Studies Showed ISENTRESS[R] in Combination Therapy Provided Significant Viral Load Reductions through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV. Feb 9, 2009 8751 New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS(R) (raltegravir) Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination with Other Medicines. Oct 26, 2008 8191 Major Government Clinical Study Approved for Anadis' AIDS Therapy. Oct 21, 2008 563 Dual drug class resistance in two-thirds of those failing antiretroviral therapy in South Africa. Farham, Bridget Report Jul 1, 2008 581 Start antiretroviral therapy at higher CD4 counts to improve outcome. Farham, Bridget Feb 1, 2008 633 ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks. Sep 18, 2007 1248 Examining the rollout of pediatric antiretroviral treatment in South Africa. May 1, 2007 1642 To Slow AIDS in Russia, Treat HIV-Positive Addicts, Stanford Study Says. Nov 9, 2006 789 Older patients more compliant with antiretroviral therapy. Lowry, Fran Nov 1, 2006 352 REPEAT/Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT). Oct 2, 2006 1150 Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT). Sep 29, 2006 1150 Antiretroviral drug resistance and routine therapy, Cameroon. Delaporte, Eric Jun 1, 2006 2531 Study finds 3,000,000 years of life saved by HIV treatment in the U.S. Jan 1, 2006 103 Major study of "discordant" response--viral control but incomplete CD4 response. James, John S. Jun 24, 2005 333 Immunology study finds decreased activation markers related to better viral control. James, John S. Jun 24, 2005 253 Four antiretrovirals reduced to three after 48 weeks. James, John S. Brief Article Jun 24, 2005 160 Ten years of HAART. Harrington, Mark Jun 22, 2005 4496 Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. James, John S. Interview Nov 1, 2004 1648 Treatment interruption: most patients could not maintain immune control. James, John S. Nov 1, 2004 395 Nevirapine misinformation: will it kill? James, John S. Nov 1, 2004 2937 Regulatory issues and challenges in salvage therapy: (a personal take on Panel 4. Discussion leader: Trip Gulick). Delaney, Martin Jun 22, 2004 924 SMART study. Brief Article Jun 1, 2004 240 Inhibition of HIV fusion: challenges for correctional health care. Macher, Abe; Thomas, David; Mayne, Donna; Schuster-Walker, Marmie; Weedon, Joey; Falcon, Ron Jan 1, 2004 4420